New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
07:21 EDTAGN, VRXValeant recent weakness a buying opportunity, says JPMorgan
JPMorgan recommends using the recent pullback in shares of Valeant (VRX) as a buying opportunity. After meeting with management, the firm has increased confidence in the company's ability to show accelerating top-line growth in the second half of 2014. It sees "compelling value" in Valeant shares regardless of the Allergan (AGN) outcome and keeps an Overweight rating on the stock with a $180 price target.
News For VRX;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 28, 2015
10:19 EDTVRXPershing Square lists Herbalife, Actavis as top Q1 losers
Subscribe for More Information
April 27, 2015
06:19 EDTVRXPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use